3D 세포배양 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

3D Cell Culture Market Growth & Trends:

The global 3D cell culture market size is expected to reach USD 3.21 billion by 2030, registering a CAGR of 11.72% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by technological advancements in in-vitro testing models, a rising focus on personalized medicine, and supportive government legislation for R&D. Moreover, the increasing prevalence of chronic disorders, and the growing significance of cell therapies in their treatment have created momentum for industry expansion.

Tissue engineering has made significant developments in creating 3D culture models that mimic the in-vivo culture media more precisely than the conventional 2D cell cultures. This resulted in increased utilization of 3D cell culture systems for toxicity testing, drug discovery, and regenerative medicine development. Also, recent product launches from industry players have supported market growth to a significant extent. For instance, in June 2023, Pixelgen Technologies launched its first molecular pixelation kit for 3D spatial study of proteins present on cell surface.

In addition, the development of advanced technologies like microfluidics, bioprinting, and high-content screening systems, has leveraged the capabilities of these models. These technologies allow excellent control over culture conditions, cell organization, and the capability to perform high-efficiency screening, thereby fueling the utilization of 3D culture systems. Moreover, increased collaboration between market players to utilize bioprinting and microfluidics techniques in developing culture models has propelled market growth. For instance, in June 2023, AIM Biotech and MatTek partnered together to offer innovative idenTX and organiX microfluidic 3D tissue culture platforms along with complete drug discovery research services in specific areas of neurobiology, immune-oncology, and vascular biology.

3D cultures can closely replicate the typical microarchitecture and morphology of organs and hence are continuously developed for studies that require in vivo models to analyze the effect of a drug over body tissues and organs. This factor, coupled with the availability of several choices in terms of the material and structure of the scaffold for a variety of in-vitro applications, is anticipated to boost revenue generation for scaffolds. Recent research has explored the use of a broad range of scaffolds, such as graphene scaffolds, nanofibers, natural marine collagen, freeze-casting, and others. In addition, emerging applications of techniques such as lab-on-a-chip in several assay types, including proliferation, stimulation, viability, transport, high content screening, patch clamping, and metabolic activity are anticipated to lead to an increase in demand for advanced and efficient solutions.

However, the lack of consistency in 3D cell model products is one of the major drawbacks that is expected to hinder the growth of the market. Moreover, various factors such as variability in cell culture, standardized challenges, scale & manufacturing issues, and quality control issues might hamper the market growth.

3D Cell Culture Market Report Highlights:

• The scaffold-based segment held the largest revenue share of 48.85% in 2024. The segment is divided into hydrogels, polymeric scaffolds, micropatterned surfaced microplates, and nanofiber-based scaffolds.
• The stem cell research & tissue engineering segment dominated the market with a share of 34.23% in 2024. The market is segmented into cancer research, stem cell research & tissue engineering, drug development & toxicity testing, and others.
• In the end-use segment, the biopharmaceutical & pharmaceutical companies segment dominated the market with a share of 46.93% in 2024. The market is segmented into biotechnology & pharmaceutical companies, academic & research institutes, hospitals, and others.
• North America 3D cell culture market dominated the global market and accounted for 39.09% share in 2024. The market is collectively driven by the presence of advanced healthcare infrastructure, developed economies, the presence of key players, and various strategic initiatives undertaken by them.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Technology Segment
  • 1.1.2. Application Segment
  • 1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis:
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing demand for organ transplantation & tissue engineering
    • 3.2.1.2. Technological advancements in scaffold free technology
    • 3.2.1.3. Rise in investments and R&D funding for cell-based research
    • 3.2.1.4. Increasing focus on developing alternative to animal testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost associated with implementation
    • 3.2.2.2. Lack of compatibility and consistency
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

• 4.1. 3D Cell Culture Market: Technology Movement Analysis
• 4.2. Scaffold Based
  • 4.2.1. Scaffold based market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.2.2. Hydrogels
    • 4.2.2.1. Hydrogels market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.2.3. Polymeric Scaffolds
    • 4.2.3.1. Polymeric scaffolds market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.2.4. Micropatterned Surface Microplates
    • 4.2.4.1. Micropatterned surface microplates market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.2.5. Nanofiber Based Scaffolds
    • 4.2.5.1. Nanofiber based scaffolds market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.3. Scaffold Free
  • 4.3.1. Scaffold free market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Hanging Drop Microplates
    • 4.3.2.1. Hanging drop microplates market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Spheroid Microplates with ULA coating
    • 4.3.3.1. Spheroid microplates with ULA coating market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. Magnetic Levitation
    • 4.3.4.1. Magnetic levitation market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.4. Bioreactors
  • 4.4.1. Bioreactors market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Microfluidics
  • 4.5.1. Microfluidics market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6. Bioprinting
  • 4.6.1. Bioprinting market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. 3D Cell Culture Market: Application Movement Analysis
• 5.2. Cancer Research
  • 5.2.1. Cancer research market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.3. Stem Cell Research & Tissue Engineering
  • 5.3.1. Stem cell research & tissue engineering market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.4. Drug Development & Toxicity Testing
  • 5.4.1. Drug development & toxicity testing market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. 3D Cell Culture Market: End Use Movement Analysis
• 6.2. Biotechnology & Pharmaceutical Companies
  • 6.2.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.3. Academic & Research Institutes
  • 6.3.1. Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospital market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. 3D Cell Culture Share By Region, 2024 & 2030
• 7.2. North America
  • 7.2.1. North America 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Competitive Scenario
    • 7.2.2.3. Target Disease Prevalence
    • 7.2.2.4. U.S. 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Competitive Scenario
    • 7.2.3.3. Target Disease Prevalence
    • 7.2.3.4. Canada 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Competitive Scenario
    • 7.2.4.3. Target Disease Prevalence
    • 7.2.4.4. Mexico 3D Cell Culture, 2018 - 2030 (USD Million)
    • 7.2.4.5.
• 7.3. Europe
  • 7.3.1. Europe 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Target Disease Prevalence
    • 7.3.2.4. UK 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Target Disease Prevalence
    • 7.3.3.4. Germany 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Target Disease Prevalence
    • 7.3.4.4. France 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Competitive Scenario
    • 7.3.5.3. Target Disease Prevalence
    • 7.3.5.4. Italy 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Competitive Scenario
    • 7.3.6.3. Target Disease Prevalence
    • 7.3.6.4. Spain 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Competitive Scenario
    • 7.3.7.3. Target Disease Prevalence
    • 7.3.7.4. Denmark 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Competitive Scenario
    • 7.3.8.3. Target Disease Prevalence
    • 7.3.8.4. Sweden 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Competitive Scenario
    • 7.3.9.3. Target Disease Prevalence
    • 7.3.9.4. Norway 3D Cell Culture, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Target Disease Prevalence
    • 7.4.2.4. Japan 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Target Disease Prevalence
    • 7.4.3.4. China 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Target Disease Prevalence
    • 7.4.4.4. India 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.4.5. Australia
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Target Disease Prevalence
    • 7.4.5.4. Australia 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.4.6. Thailand
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Target Disease Prevalence
    • 7.4.6.4. Thailand 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.4.7. South Korea
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Target Disease Prevalence
    • 7.4.7.4. South Korea 3D Cell Culture, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Target Disease Prevalence
    • 7.5.2.4. Brazil 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Target Disease Prevalence
    • 7.5.3.4. Argentina 3D Cell Culture, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Target Disease Prevalence
    • 7.6.2.4. South Africa 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Target Disease Prevalence
    • 7.6.3.4. Saudi Arabia 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Target Disease Prevalence
    • 7.6.4.4. UAE 3D Cell Culture, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Target Disease Prevalence
    • 7.6.5.4. Kuwait 3D Cell Culture, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific, Inc
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. PromoCell GmbH
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Lonza
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Corning Incorporated
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Avantor, Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Tecan Trading AG
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. REPROCELL Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Product Benchmarking
    • 8.4.8.3. Strategic Initiatives
  • 8.4.9. CN Bio Innovations Ltd.
    • 8.4.9.1. Overview
    • 8.4.9.2. Product Benchmarking
    • 8.4.9.3. Strategic Initiatives
  • 8.4.10. Lena Biosciences
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives